ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY
Sarah Harris 1
Brian G. Feagan 2
Steve Hanauer 3
Severine Vermeire 4
Subrata Ghosh 5
Jim Yan 6
Chun Wu 6
Yanhua Hu 6
Rachel Maddux 6
Douglas C. Wolf 7
Geert D’Haens 8
1 Bristol Myers Squibb, Princeton, United States
2 Robarts Research Institute, Western University, London, Ontario, Canada
3 Northwestern University Feinberg School of Medicine, Chicago, United States
4 University of Leuven, Leuven, Belgium
5 APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland
6 Laboratory Corporation of America, Durham, United States
7 Center for Crohn’s Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, United States
8 Inflammatory Bowel Disease Center, Amsterdam University Medical Center, Amsterdam, Netherlands
Topic
IBD
Conference
UEG Week Copenhagen 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]